Parkinson's risk hunt: 2,200 volunteers help uncover hidden clues

NCT ID NCT03536104

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked for genetic and environmental factors that increase the risk of developing Parkinson's disease. Researchers compared DNA and lifestyle data from over 2,200 people, including Parkinson's patients, people with related brain diseases, and healthy volunteers. The goal was to find specific gene variations linked to Parkinson's and understand how they interact with things like environment and biology.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify people at higher risk for Parkinson's disease and point toward potential targets for future treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear genetic links, and any findings will need much more research before they could help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,220 people

The number who actually took part.

Started

Mar 2009

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Parkinson Disease compared to subjects at risk to develop Parkinson Disease and healthy controls

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria for Parkinson's patients and "related diseases" controls: * Parkinsonian patients meeting the Gelb criteria * Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease). * Woman of childbearing age having an effective means of contraception. * Informed consent signed by the subject or his legal representative. * For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative. Criteria for inclusion of non-ill controls: * Absence of rest trembling, bradykinesia and stiffness * MMSE (Mini Mental State Examination) greater than 25 * Woman of childbearing age having an effective means of contraception. * subject having signed the informed consent. * No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test. Exclusion Criteria: * Criteria for non-inclusion of patients: * Clinical criteria for exclusion of the diseases described * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial. Criteria for non-inclusion of non-ill controls: * Functional discomfort in daily life of unknown cause * MMSE less than 25 * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Roger Salengro, CHRU de Lille

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.